|Anti-CHMP5 single chain variable fragment antibody retrovirus infection induces programmed cell death of AML leukemic cells in vitro.|
|Jump to Full Text|
|PMID: 22609838 Owner: NLM Status: MEDLINE|
|AIM: Over-expressed CHMP5 was found to act as oncogene that probably participated in leukemogenesis. In this study, we constructed the CHMP5 single chain variable fragment antibody (CHMP5-scFv) retrovirus and studied the changes of programmed cell death (PCD) of AML leukemic cells after infection by the retrovirus.
METHODS: The anti-CHMP5 KC14 hybridoma cell line was constructed to generate monoclonal antibody of CHMP5. The protein expression of CHMP5 was studied using immunofluorescence analysis. pMIG-CHMP5 scFv antibody expressible retroviral vector was constructed to prepare CHMP5-scFv retrovirus. AML leukemic U937 cells were infected with the retrovirus, and programmed cell death was studied using confocal microscope, FCM and Western blot.
RESULTS: We obtained a monoclonal antibody of CHMP5, and found the expression of CHMP5 was up-regulated in the leukemic cells. After U937 cells were infected with CHMP5-scFv retrovirus, CHMP5 protein was neutralized. Moreover, the infection resulted in a significant increase in apoptosis and necrosis of U937 cells. In U937 cells infected with CHMP5-scFv retrovirus, apoptosis-inducing factor (AIF)-mediated caspase-independent necrotic PCD was activated, but autophagic programmed cell death was not observed. Neither the intrinsic nor extrinsic apoptotic PCD pathway was activated. The granzyme B/perforin-mediated caspase-dependent apoptotic PCD pathway was not activated.
CONCLUSION: CHMP5-scFv retrovirus can neutralize the abnormally high levels of the CHMP5 protein in the cytosol of AML leukemic U937 cells, thereby inducing the programmed cell death of the leukemic cells via AIF-mediated caspase-independent necrosis and apoptosis.
|Hai-rong Wang; Zhen-yu Xiao; Miao Chen; Fei-long Wang; Jia Liu; Hua Zhong; Ji-hua Zhong; Ren-rong Ou-Yang; Yan-lin Shen; Shu-ming Pan|
Related Documents :
|21091848 - Differential antiproliferation effect of 2'-benzoyloxycinnamaldehyde in k-ras-transform...
22788718 - Buffalo (bubalus bubalis) es cell-like cells are capable of in vitro skeletal myogenic ...
22778098 - Campylobacter jejuni translocation across intestinal epithelial cells is facilitated by...
22609838 - Anti-chmp5 single chain variable fragment antibody retrovirus infection induces program...
7275188 - Opposing changes in electrokinetic potential of spleen cells induced by factors from di...
16258628 - Symmetric pollen mitosis i and suppression of pollen mitosis ii prevent pollen developm...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-05-21|
|Title: Acta pharmacologica Sinica Volume: 33 ISSN: 1745-7254 ISO Abbreviation: Acta Pharmacol. Sin. Publication Date: 2012 Jun|
|Created Date: 2012-06-07 Completed Date: 2012-10-15 Revised Date: 2014-10-16|
Medline Journal Info:
|Nlm Unique ID: 100956087 Medline TA: Acta Pharmacol Sin Country: United States|
|Languages: eng Pagination: 809-16 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Endosomal Sorting Complexes Required for Transport / genetics, immunology*
Gene Expression Regulation, Neoplastic
Leukemia, Myeloid, Acute / genetics, immunology*, virology*
Mice, Inbred BALB C
Retroviridae / genetics, immunology*
Retroviridae Infections / complications, immunology
Single-Chain Antibodies / genetics, immunology*
|0/CHMP5 protein, human; 0/Endosomal Sorting Complexes Required for Transport; 0/Single-Chain Antibodies|
Journal ID (nlm-ta): Acta Pharmacol Sin
Journal ID (iso-abbrev): Acta Pharmacol. Sin
Publisher: Nature Publishing Group
Copyright © 2012 CPS and SIMM
Received Day: 09 Month: 02 Year: 2012
Accepted Day: 23 Month: 03 Year: 2012
Print publication date: Month: 06 Year: 2012
Electronic publication date: Day: 21 Month: 05 Year: 2012
Volume: 33 Issue: 6
First Page: 809 Last Page: 816
PubMed Id: 22609838
Publisher Item Identifier: aps201238
|Anti-CHMP5 single chain variable fragment antibody retrovirus infection induces programmed cell death of AML leukemic cells in vitro|
1Emergency Department, Xin-Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
2Department of Hematology, Ren-Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
3Shanghai Institute of Hematology, Shanghai 200025, China
4Department of Pharmacy, Xin-Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
#These authors contributed equally to this work.
In adults, acute myeloid leukemia (AML) is by far the most common type of acute leukemia. It is a cancer of the bone marrow and is characterized by a mutation in a hematopoietic stem or progenitor cell, which develops into the accumulation of highly proliferative dysfunctional and immature myeloid cells. These abnormal cells eventually dominate hematopoietic niches, such as the bone marrow, and result in abnormal peripheral blood counts due to high number of myeloblasts. Over the past several decades, improvements in chemotherapeutic regimens and supportive care have resulted in significant but modest progress in treating AML, but AML remains a fatal disease for most patients1. A better molecular definition and the elucidation of the physiopathology of AML combined with the development of new and targeted therapies may result in a better prognosis for patients with AML in the future.
The human charged multivesicular body protein 5 (CHMP5) is a member of the CHMP family of coiled-coil proteins2. The multivesicular body (MVB) is a particular type of late endosomes, which are crucial intermediates in the internalization of nutrients, ligands and receptors through the endolysosomal system. It plays a crucial role in sorting membrane proteins that are destined for degradation or routing to the lysosome3, 4. These proteins, such as activated growth-factor, hormone and cytokine receptors, are internalized into vesicles forming an MVB, the contents of the MVB are then transferred to lysosomes for degradation2, 5, 6. CHMP5 is responsible for the final conversion of late endosomal MVB to lysosomes and plays a critical role in the downregulation of signaling pathways through receptor degradation2, 7.
Functional analyses of CHMP5 are performed using an RNAi and protein overexpression strategy in our lab. We found CHMP5 is an anti-apoptotic gene8, which is consistent with previous findings by Shahmoradgoli et al9. Moreover, our data confirmed previous findings showing that CHMP5 is significantly increased in de novo or relapsed acute myeloid leukemia, indicating that it may participate in leukemogenesis8, 9. Immunofluorescence experiments using a monoclonal antibody produced by our lab suggested that the CHMP5 protein was expressed at low levels in the cytosol of 293T cells and normal blood mononuclear cells from healthy volunteers. Interestingly, the CHMP5 protein was highly expressed in the cytosol of AML leukemic cells (unpublished data). These findings indicate that highly expressed CHMP5 protein may participate in leukemogenesis, and the abnormal expression of the CHMP5 protein may be a target for gene therapy.
Recently, recombinant antibodies targeting tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), gene therapy and immunomodulators have transformed the traditional chemotherapy based only on anticancer drugs. TAAs or TSAs are proteins or other molecular species that are expressed in a specific tumor type that can be targeted for diagnostic and immunotherapy purposes10. Tumor-specific recombinant antibodies have been employed in diagnosis and therapy, such as the anti-CD20 monoclonal antibody (McAb), either as single agents or in combination with chemotherapy. These agents have resulted in large improvements in non-Hodgkin's lymphoma survival rates. The main pitfalls of utilizing antibodies to tumor-specific antigens in cancer diagnosis and therapy are the immune response to non-human antibodies and the large size of antibodies, which hinders their access to the large tumors or into cells10.
The first single chain variable fragment antibody (scFv) was developed in 1988. An scFv is an antibody composed of heavy- and light-chain variable regions that are joined by an interchain polypeptide linker. The scFv is one of the smallest fragments to be produced that shows equivalent binding affinity to the parent Fab (fragment antigen-binding) fragment11, 12. ScFv can be conjugated to different types of molecules, such as radioisotopes and toxins, or expressed as an intracellular antibody (intrabody) in a specific intracellular compartment, where it can interfere with the function of the targeted antigen at the level of a specific domain13. Human single chain antibody fragments offer the advantage of being expressed as a single polypeptide, and their small size means that they can serve as a highly safe, selective and effective diagnostic and therapeutical tool10, 14, 15, 16, 17, 18, 19, 20. The scFv on target molecules within cells or intrabodies provides a useful tool for research as well as for control of diseases such as human immunodeficiency virus type 1 infection and other diseases13, 15, 16, 21.
As we mentioned previously, the expression of the anti-apoptotic protein CHMP5 was dramatically up-regulated in the cytosol of AML leukemic cells, which was distinct from the expression in normal mononuclear cells. Infecting AML leukemic cells with an anti-CHMP5 scFv retrovirus may induce programmed cell death by neutralizing the excess anti-apoptotic CHMP5 protein.
Human HEK293T (human embryonic kidney) cells and U937 cells were obtained from the Shanghai Institute of Hematology (Shanghai, China). The anti-CHMP5 KC14 hybridoma cell line was constructed by our lab. The cells were cultured in RPMI-1640 supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin at 37 °C and 5% (v/v) CO2. The media for culturing the hybridoma cell line KC14 contained 1×HAT (Hypoxathine, Aminopterin and Thymidine).
Antheprot 4.3 was used to select three antigenic epitopes of the CHMP5 protein. These antigenic epitopes were synthesized and used to generate the CHMP5 polyclonal antibody. Western blot analysis revealed that the polyclonal antibody derived from the KC14 antigenic epitope performed best. The amino acid sequence of KC14 was N'-KAK PKA PPP SLT DC-C'. The hybridoma was constructed according to Ball et al22. Briefly, we conjugated the KC14 peptide to bovine serum albumin (BSA). BALB/c mice were immunized against the synthetic peptide of the CHMP5 protein. The spleen cells of the mice were fused with Sp2/0 mouse myeloma cells. The titers of the monoclonal antibody (McAb) were tested by ELISA.
Total RNA extracted from the KC14 hybridoma was converted into cDNA using reverse transcriptase. PCR was performed with mouse primers for VL and VH. The primers were designed according to references23, 24. The VL sense primer was: 5'-CCT CTA GAG ACA TTG TG-3'; the VL antisense primer was: 5'-GCC CTT GGC TCG AGT TTT-3'; the VH sense primer was: 5'-ATG AGT CCT GAA CTA ACC TTG AAT C-3'; and the VH antisense primer was: 5'-TCA TTC TAG CCC TTT CCC TGT AGC C-3'. PCR products were purified, TOPO-TA was cloned into the T-vector, and the recombinant vector was sequenced to obtain DNA sequence of VL and VH.
The pBabe-puro retroviral vector was obtained from the Shanghai Institute of Hematology (Shanghai, China). We first inserted the VL sequences into pBabe to generate the pBabe-VL recombinant vector. The VL sense primer included restriction sites for the endonuclease BamH I, and the antisense primer included restriction sites for the endonuclease EcoR I. PCR was performed using cDNA of the KC14 hybridoma cells to obtain VL sequences. The purified PCR products and the pBabe-Puro retroviral vector were digested with restriction enzymes BamH I and EcoR I, respectively. The DNA Ligation Kit Ver 2.0 (Takara, Tokyo, Japan) was used to ligate the VL sequences with pBabe to produce the pBabe-VL recombinant vector. Subsequently, we chemically synthesized a linker oligonucleotide. The sense sequence of linker was 5'-AAT TCG GTG GTG GTG GAT CCG GTG GTG GTG GTT CTG GCG GCG GCG GCT CCG-3' and the antisense sequence of linker was 5'-TCG ACG GAG CCG CCG CCG CCA GAA CCA CCA CCA CCG GAT CCA CCA CCA CCG-3'. The underlined portion shows the EcoR I site. After annealing with its counterpart oligonucleotide, the EcoR I sticky end may form at the 5' terminal end of the linker dsDNA. The Sal I site is shown in italics. After annealing with its counterpart oligonucleotide, the Sal I sticky end may form at the 3' terminal end of the linker dsDNA. After the pBabe-VL recombinant vector was cut with the EcoR I and Sal I restriction enzymes, the linker dsDNA was introduced to form the pBabe-VL-linker recombinant vector. Subsequently, both VH sense and antisense primers were added with restriction sites for the endonuclease Sal I and VH was introduced into pBabe-VL-linker to form the pBabe-CHMP5 scFv antibody retroviral expression vector.
The pMIG-GFP retroviral vector, gag/pol and VSV-G were obtained from the Shanghai Institute of Hematology (Shanghai, China). Because the pBabe-CHMP5 scFv antibody retroviral expression vector did not contain the GFP (green fluorescence protein) sequence, it was difficult for us to evaluate the infection efficiency after transient transfection. Therefore, we utilized the pMIG-GFP retroviral vector to construct pMIG-CHMP5 scFv antibody retroviral expression vector. The primer pairs 5'-tac gtt aga tctATG ACC CAG TCT CCT GCT-3' and 5'-tag att gtt aac GCA TTC TAG CCC TTT CCC-3' were used, and the pBabe-CHMP5 scFv antibody retroviral expression vector served as the DNA template for PCR to obtain the CHMP5 scFv sequence. The purified PCR products and the pMIG-GFP retroviral vector were digested with the Bgl I and Hpa I restriction enzymes, respectively. The DNA Ligation Kit Ver 2.0 was used to ligate the CHMP5 scFv sequence with pMIG to generate the pMIG-CHMP5 scFv antibody retroviral expression vector.
To prepare the virus, 293T cells were cotransfected with the empty pMIG vector or the pMIG-CHMP5 scFv antibody retroviral expression plasmid and gag/pol and VSV-G using the FuGENE 6 transfection reagent (Roche, USA)25, 26. One day after transfection, the medium was changed, and collection of the virus-containing medium began on d 2. The medium was filtered through a 0.22-μm filter. U937 cells were then infected with the retroviral supernatants. The clones expressing the desired genes were sorted by a flowcytometer (FCM), and the GFP-positive cells were selected26.
Our CHMP5 McAb was used to detect the CHMP5 protein in U937 cells by immunofluorescence after infected by the scFv retrovirus. The cells were incubated with primary antibodies and the anti-mouse secondary antibody was CY3-conjugated. The images were captured by confocal laser scanning microscope (Carl Zeiss, ObErkochen, Germany). To avoid experimental error, non-infected U937 cells served as the control and the parameters of the microscope were fixed in each experiment. The typical field of the microscope was selected by the operator of the confocal laser scanning microscope.
The cells were stained with annexin-allophycocyanin (APC)/7-amino-actinomycin (7-AAD) (BD PharMingen, San Jose, CA, USA) and evaluated using FCM. APC was optimized for FL-4 fluorescence on a flowcytometer, and 7-AAD fluorescence was detected in the far red range of the spectrum (650 nm long-pass filter)8. The results were represented as the percentage of both annexin V-APC+/7-AAD− and annexin V-APC+/7-AAD+ cells. For confocal microscopy, the excitation wavelength of annexin V-APC was 633 nm and the emission wavelength was 700–780 nm8. The excitation wavelength of 7-AAD was 543 nm and the emission wavelength was 560–615 nm. A total of 200 cells were counted, and the results were calculated based on the percentages of both annexin V-APC+/7-AAD− and annexin V-APC+/7-AAD+ cells.
Western blot was performed using PCD-associated antibodies. The Granzyme B, microtubule-associated protein 1 light chain 3 (LC-3) and Caspase 9 antibodies were purchased from Cell Signal Technology (MA, USA); AIF and Caspase 3 antibodies were purchased from Epitmics (CA, USA); antibodies against PARP were purchased from Santa Cruz Biotechnology (CA, USA); anti-Caspase 8 was purchased from BD Pharmingen (CA, USA).
The changes in gene and protein expression of CHMP5 in U937 cells after scFv retrovirus infection were studied. Reverse transcription polymerase chain reaction (RT-PCR) was performed, and the CHMP5 primers were: 5'-TGC TCA AGA TGA ACC GAC TCT-3' and 5'-GTG GGA ACA CCT TCT GGA AT-3'. The β-actin primers were: 5'-TCG ACA ACG GCT CCG GCA T-3' and 5'-AAG GTG TGG TGC CAG ATT TTC-3'. The polyclonal antibody against CHMP5 that was used for Western blot analysis was purchased from Abcam (Cambridge, UK).
All statistics were performed using SAS 6.12 software. Data were expressed as mean±SD from three independent experiments. The statistical significance was determined using t-test to compare groups of data. P values <0.05 were considered to be statistically significant.
Because a monoclonal antibody of CHMP5 was not commercially available and we needed to obtain the VL and VH sequence of anti-CHMP5 hybridoma cells, we constructed hybridoma cells and produced our own CHMP5 monoclonal antibody. After we obtained the monoclonal antibody of CHMP5, both Western blot analysis and immunofluorescence studies verified that McAb functioned as expected (Figure 1). The U937 group consisted of U937 cells that were not transfected with plasmids. The sh Con group consisted of U937 cells that were transfected with short-hairpin RNA (shRNA) control plasmids. The sh-CHMP5 group was composed of cells with RNA interference-mediated CHMP5 inhibition8. We found that our monoclonal antibody could detect an approximately 28 kDa band in the U937 and sh Con groups by Western blot analysis; however, this band was very weak in the sh-CHMP5 group. The reduction in the density of the band was consistent with the changes in CHMP5 expression, indicating that this McAb could be utilized to detect CHMP5 protein by Western blot (Figure 1A). The McAb immunofluorescence (IF) results also confirmed that we had successfully prepared the McAb. Figure 1B–1D show the immunofluorescence results of the U937, sh Con and sh-CHMP5 groups, respectively. The figure shows the merged by red and blue fluorescence images. The red fluorescence (CY3) represents CHMP5 protein, and the blue fluorescence represents the DAPI (diamidino-phenyl-indole) signal, which labeles the nucleus. We found that the red fluorescence signal of the CHMP5 protein was highly expressed throughout cytosol (Figure 1A and 1B), but the red fluorescence signal decreased after CHMP5 was inhibited by RNA interference (Figure 1C). The change in red fluorescence was consistent with the changes in CHMP5 expression, indicating that this McAb may be utilized for immunofluorescence.
The detailed DNA sequencing results of the cloned VL and VH of the scFv were supplied in the supplemental data.
IgBLAST and Nucleotide blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi) were employed, and we confirmed that the sequences of VL and VH we obtained represented the variable region. VL shares 98% identity (281/288) to the Mus musculus strain C57BL/6J chromosome 6 genomic contig (NT 039353.7). At this site, the Mus musculus light chain gene Igk-V21-12 is represented (GeneID: 667914). The VH was on the Mus musculus strain 129/SvJ chromosome 12 unlocalized genomic contig (NT 114985.2), and this site included the Mus musculus heavy chain gene Igh-VX24 (GeneID: 195176). The VH appeared to be the composite of two fragments, and each fragment showed high similarity (98% and 100%, respectively) to Igh-VX24.
The non-infected U937 group showed CHMP5 protein expression (red fluorescence) distributed throughout the cytosol. The GFP protein could not be detected because it was not infected (Figure 2). The scFv-Con group (U937 cells were infected by empty pMIG-GFP) displayed GFP expression, indicating that the retrovirus had successfully infected U937 cells, and we could note that the expression of the CHMP5 protein was similar to the level observed in the U937 cells (Figure 2). The scFv-virus group (U937 cells infected with the pMIG-CHMP5 scFv retrovirus) showed GFP expression, indicating that the virus had successfully infected U937 cells. We found that the red fluorescence decreased dramatically, and the remaining red fluorescence appeared to exist as particulates in cytosol (Figure 2).
By FCM, we found that the apoptosis rate was 1.60%±0.24% in U937 group, and 1.81%±0.11% and 10.19%±0.46% in the scFv-Con and scFv-CHMP5 groups, respectively. There were no statistically significant differences between the U937 and scFv-Con groups (P=0.1217). There was a statistically significant difference between the scFv-Con and scFv-CHMP5 groups (P=0.0015) (Figure 3A). The apoptosis rate increased approximately 5 times following the scFv retrovirus infection. We used confocal microscopy to further demonstrate that the apoptosis rate was 3.27% in the U937 group, 3.54% in the scFv-Con group and 12.36% in the scFv-CHMP5 group, in agreement with the FCM results (Figure 3B–3D). We also found that the percentage of 7-AAD single-stained cells increased, which was likely necrosis27, 28 (Figure 3D).
After we showed that the scFv retrovirus infection could induce U937 leukemic cells to undergo apoptosis, Western blot analysis was applied to study the changes in the apoptotic pathway. The autophagic and necrotic programmed cell death pathways were also examined. We found that after U937 cells were infected by the scFv retrovirus, the expression of AIF and cleaved Caspase 3 increased (Figure 4). PARP was the substrate of the activated Caspase 3, and we found that PARP decreased and its cleavage increased after scFv retrovirus infection. Granzyme B (Gran B), proCaspase 8, cleaved Caspase 8 and cleaved Caspase 9 showed no obvious changes. Neither the conversion of LC3-I to LC3-II nor the increase of LC3-II was observed after scFv retrovirus infection (Figure 4).
To detect whether scFv retrovirus infection could affect the gene expression in U937 cells, reverse transcript PCR was used. We found the gene expression was not altered after scFv retrovirus infection. The change in CHMP5 protein expression after scFv retrovirus infection was also studied by Western blot using a polyclonal antibody purchased from Abcam. We found that the protein expression was also not changed after scFv retrovirus infection (Figure 5).
As we have mentioned previously, immunofluorescence experiments using a monoclonal antibody produced by our lab suggested that the CHMP5 protein was expressed at relatively low levels in the cytosol of 293T cells and normal blood mononuclear cells from healthy volunteers. Conversely, the CHMP5 protein was highly expressed in the cytosol of AML leukemic cells (unpublished data). Moreover, our studies are consistent with previous studies which show that CHMP5 is an anti-apoptotic gene8, 9. Furthermore, in agreement with these previous studies, we found that the CHMP5 gene expression is significantly increased in de novo or relapsed AML, indicating that it may participate in leukemogenesis8, 9. As shown in Figure 1, after CHMP5 is inhibited by RNA interference in the AML leukemic cell line, U937, the expression of the CHMP5 protein is significantly decreased, and the leukemic cells are induced to undergo apoptosis8. These findings indicate that highly expressed CHMP5 protein in the cytosol may participate in leukemogenesis, and it may be a target for gene therapy.
The scFv to target molecules within cells provide a useful tool for research as well as for the control of diseases13, 15, 16, 21. To produce a scFv-CHMP5, the hybridoma cells should be created, and subsequently the VL and VH variable region from the RNA of hybridoma cells must be obtained29. Immunofluorescence revealed that when the U937 cells were infected by the scFv-CHMP5 retrovirus, the red fluorescence of the CHMP5 protein decreased dramatically. Because the VL and VH variable regions of the CHMP5 scFv are generated from the RNA of hybridoma cells, which are also used to produce the McAb of CHMP5, the antigenic site of CHMP5 is shared and recognized by scFv and McAb. Immunofluoresence with this monoclonal antibody shows a decrease of red fluorescence (CHMP5 protein) after scFv retrovirus infection. This reduction may be explained by two potential scenarios; after the CHMP5 protein is neutralized by the scFv, the amount of CHMP5 protein in cytosol is not altered or CHMP5 is degraded. Both the gene and protein expression level of CHMP5 are studied, and the results indicate its gene expression level and the amount of CHMP5 protein in cytosol are not altered after being neutralized by scFv (Figure 5). Notably, we find little red fluorescence remains in the cytosol after scFv-virus infection, and this red fluorescence appears to be in the particulates in the cytosol. Ward et al has reported that the CHMP5 protein is likely to be found in vesicles, which are thought to be lysosome and MVB7. Consistent with this observation, we suggest that the CHMP5 protein, which has been neutralized by scFv, is in cytosol, whereas the remaining CHMP5 protein is localized to the lysosome and MVB.
Recently, apoptosis was classified as type I programmed cell death30. Our previous study had found that both the Granzyme B/Perforin-mediated apoptotic and AIF-mediated necrotic programmed cell death pathways are activated during CHMP5 deficiencies, whereas the autophagic programmed cell death is not activated (unpublished data). Therefore, these PCD pathways were studied in U937 cells after scFv retrovirus infection. In general, activation of Caspase 9 results in the initiation of the intrinsic pathway, whereas activation of Caspase 8 results in the initiation of the extrinsic pathway31. Activation of either pathway leads to activation of the downstream Caspase 3 and Caspase 7. We find that Caspase 3 is activated after U937 cells are infected by scFv retrovirus, indicating the apoptotic PCD pathway is activated. Neither Caspase 8 nor Caspase 9 is activated, indicating that neither intrinsic and extrinsic apoptotic PCD pathways are activated. To our surprise, the granzyme B/perforin-mediated Caspase-dependent apoptotic PCD pathway is also not activated. Although the apoptosis-inducing protein, AIF, increased after scFv retrovirus infection, AIF is thought to activiate Caspase-independent necrotic PCD pathways. That is, it is considered to be unable to active Caspase 332, 33. It appears that an additional uncommon Caspase-dependent apoptotic PCD pathway is activated, or this may indicate that AIF can active Caspase 3.
AIF-induced apoptosis now is reported to be Caspase-independent necroptosis32, and necrosis is thought to be type III programmed cell death30. Increasing evidence shows that necrosis is a highly orchestrated type of PCD32, 33. Upon activation of PCD, AIF is released from the mitochondria and translocated into the nucleus to induce phosphatidylserine exposure, chromatin condensation and DNA fragmentation27, 28. We find that AIF increases after scFV retrovirus infection in U937 cells. Phosphatidylserine exposure can be detected by annexin V, and we find that both phosphatidylserine exposure and chromatin condensation can be found in U937 cells after scFV retrovirus infection (Figure 3D), indicating that AIF-mediated caspase-independent necrosis is activated.
Recently, autophagy has also been shown to be a genetically programmed and regulated process by which cells undergo self-elimination. It is classified as type II programmed cell death30. In mammals, the conversion of the microtubule-associated protein 1 light chain 3 (LC3) from LC3-I (free form) to LC3-II (phosphatidylethanolamine-conjugated form) or the increase of LC3-II is a key step in autophagy34. We find that neither the conversion of protein LC3-I to LC3-II nor the amount of LC3-II is increased. These findings indicate that autophagic programmed cell death is not observed in U937 cells after scFV virus infection.
In conclusion, we find that the scFv-CHMP5 virus can neutralize the abnormally high levels of the CHMP5 protein in the cytosol of AML leukemic U937 cells, thereby inducing leukemic cells to undergo programmed cell death via AIF-mediated caspase-independent necrosis and apoptosis. Althought this is a pilot report, our findings provide a potential method to treat AML.
AML, acute myeloid leukemia; CHMP5, charged multivesicular body protein 5; MVB, multivesicular body; ESCRT, endosomal sorting complex required for transport; scFv, single chain variable fragments antibody; PCD, programmed cell death; AIF, apoptosis inducing factor.
Hai-rong WANG designed research, performed research and wrote the paper; Zhen-yu XIAO, Miao CHEN, Fei-long WANG, Jia LIU, Hua ZHONG, Ji-hua ZHONG, and Yan-lin SHEN performed research and analyzed data; Ren-rong OU-YANG and Shu-ming PAN analyzed data and revised the paper.
This work was supported by the National Natural Science Foundation of China (30670881 and 81000212), the Shanghai Municipal Health Bureau (2009Y031) and a cooperative project of the Renji-Foundation Medical School (ZD0704). We would like to thank Dr Qiang-su GUO from the Key Laboratory for Reproductive Medicine, Shanghai Jiao Tong University School of Medicine, for his technical assistance.
|Jabbour EJ,Estey E,Kantarjian HM. Adult acute myeloid leukemiaMayo Clin ProcYear: 2006812476016471082|
|Shim JH,Xiao C,Hayden MS,Lee KY,Trombetta ES,Pypaert M,et al. CHMP5 is essential for late endosome function and down-regulation of receptor signaling during mouse embryogenesisJ Cell BiolYear: 200617210455616567502|
|Katzmann DJ,Odorizzi G,Emr SD. Receptor downregulation and multivesicular-body sortingNat Rev Mol Cell BiolYear: 2002389390512461556|
|Raiborg C,Rusten TE,Stenmark H. Protein sorting into multivesicular endosomesCurr Opin Cell BiolYear: 2003154465512892785|
|Raiborg C,Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteinsNatureYear: 20094584455219325624|
|Wollert T,Hurley JH. Molecular mechanism of multivesicular body biogenesis by ESCRT complexesNatureYear: 2010464864920305637|
|Ward DM,Vaughn MB,Shiflett SL,White PL,Pollock AL,Hill J,et al. The role of LIP5 and CHMP5 in multivesicular body formation and HIV-1 budding in mammalian cellsJ Biol ChemYear: 2005280105485515644320|
|Wang HR,Gu CH,Zhu JY,Han JY,Zhong H,Chen FY,et al. PNAS-2: a novel gene probably participating in leukemogenesisOncologyYear: 200671423917855796|
|Shahmoradgoli M,Mannherz O,Engel F,Heck S,Krämer A,Seiffert M,et al. Antiapoptotic function of charged multivesicular body protein 5: a potentially relevant gene in acute myeloid leukemiaInt J CancerYear: 201112828657120734392|
|Accardi L,Di Bonito P. Antibodies in single-chain format against tumour-associated antigens: present and future applicationsCurr Med ChemYear: 20101717305520345346|
|Huston JS,Levinson D,Mudgett-Hunter M,Tai MS,Novotný J,Margolies MN,et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coliProc Natl Acad Sci U S AYear: 1988855879833045807|
|Kortt AA,Malby RL,Caldwell JB,Gruen LC,Ivancic N,Lawrence MC,et al. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complexEur J BiochemYear: 199422115178168505|
|Pérez-Martínez D,Tanaka T,Rabbitts TH. Intracellular antibodies and cancer: new technologies offer therapeutic opportunitiesBioessaysYear: 2010325899820544739|
|Lu RM,Chang YL,Chen MS,Wu HC. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug deliveryBiomaterialsYear: 20113232657421306768|
|Marasco WA,Haseltine WA,Chen SY. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibodyProc Natl Acad Sci U S AYear: 1993907889938356098|
|Levy-Mintz P,Duan L,Zhang H,Hu B,Dornadula G,Zhu M,et al. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integraseJ VirolYear: 1996708821328971011|
|Mabry R,Snavely M. Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstaclesIDrugsYear: 201013543920721825|
|ten Cate B,Bremer E,de Bruyn M,Bijma T,Samplonius D,Schwemmlein M,et al. A novel AML selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stabilityLeukemiaYear: 20092313899719262596|
|Olafsen T,Betting D,Kenanova VE,Salazar FB,Clarke P,Said J,et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomasJ Nucl MedYear: 2009501500819690034|
|Geng SS,Feng J,Li Y,Sun Y,Gu X,Huang Y,et al. Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchangeCell Mol ImmunolYear: 200634394317257497|
|Accardi L,Donà MG,Mileo AM,Paggi MG,Federico A,Torreri P,et al. Retinoblastoma-independent antiproliferative activity of novel intracellular antibodies against the E7 oncoprotein in HPV 16-positive cellsBMC CancerYear: 2011111721241471|
|Ball RK,Siegl B,Quellhorst S,Brandner G,Braun DG. Monoclonal antibodies against simian virus 40 nuclear large T tumour antigen: epitope mapping, papova virus cross-reaction and cell surface stainingEMBO JYear: 198431485916204863|
|Lou Q,Kelleher RJ Jr,Sette A,Loyall J,Southwood S,Bankert RB,et al. Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cellsBloodYear: 2004104752915054043|
|Lu M,Gong XG,Yu H,Li JY. Cloning, expression, purification, and characterization of LC-1 ScFv with GFP tagJ Zhejiang Univ Sci BYear: 20056832716052719|
|Welm AL,Kim S,Welm BE,Bishop JM. MET and MYC cooperate in mammary tumorigenesisProc Natl Acad Sci U S AYear: 20051024324915738393|
|Wang L,O'Leary H,Fortney J,Gibson LF. Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cellsBloodYear: 200711033344417638851|
|Susin SA,Lorenzo HK,Zamzami N,Marzo I,Snow BE,Brothers GM,et al. Molecular characterization of mitochondrial apoptosis-inducing factorNatureYear: 199939744169989411|
|Lee JH,Yang HS,Park KW,Kim JY,Lee MK,Jeong IY,et al. Mechanisms of thiosulfinates from Allium tuberosum L-induced apoptosis in HT-29 human colon cancer cellsToxicol LettYear: 2009188142719446247|
|Colcher D,Pavlinkova G,Beresford G,Booth BJ,Batra SK. Single-chain antibodies in pancreatic cancerAnn N Y Acad SciYear: 19998802638010415872|
|Portt L,Norman G,Clapp C,Greenwood M,Greenwood MT. Anti-apoptosis and cell survival: a reviewBiochim Biophys ActaYear: 201118132385920969895|
|Klener P Jr,Andera L,Klener P,Necas E,Zivný J. Cell death signalling pathways in the pathogenesis and therapy of haematologic malignancies: Overview of apoptotic pathwaysFolia Biol (Praha)Year: 200652344417007108|
|Delavallée L,Cabon L,Galán-Malo P,Lorenzo HK,Susin SA. AIF-mediated caspase-independent necroptosis: a new chance for targeted therapeuticsIUBMB LifeYear: 2011632213221438113|
|Boujrad H,Gubkina O,Robert N,Krantic S,Susin SA. AIF-mediated programmed necrosis: a highly regulated way to dieCell CycleYear: 200762612917912035|
|Kabeya Y,Mizushima N,Ueno T,Yamamoto A,Kirisako T,Noda T,et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processingEMBO JYear: 2000195720811060023|
5′-GTG ATG ACC CAG TCT CCT GCT TCC TTA GCT GTA TCT CTG GGG CAG AGG GCC ACC ATC TCA TAC AGG GCC AGC AAA AGT GTC AGT ACA TCT GGC TAT AGT TAT ATG CAC TGG AAC CAA CAG AAA CCA GGA CAG CCA CCC AGA CTC CTC ATC TAT CTT GTA TCC AAC CTA GAA TCT GGG GTC CCT GCC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC TTC ACC CTC AAC ATC CAT CCT GTG GAG GAG GAG GAT GCT GCA ACC TAT TAC TGT CAG CAC ATT AGG GAG CTT ACA CGT TCG GAG GAG GCA CCA AGC TGG-3′
Click here for additional data file (aps201238x1.doc)
5′-ATG AGT CCT GAA CTA ACC TTG AAT CTG AAG CAA AGG GGA TCA GCC CGA GAT TCT CAT TCA GTG ATC AAC ACT GAA CAC ACA TCC CTT ACC ATG GAT TTT GGG CTG ATT TTT TTT ATT GTT GCT CTT TTA AAA GGG GTC CAG TGT GAG GTG AGG CTT CTC GAG TCT GGA GGT GGC CTG GTG CAG CCT GGA GGA TCC CTG AAA CTC TCC TGT GCA GCC TCA GAA TTC GAT TTT AGT AGA TAC TGG ATG AGT TGG GTC CGG CAG GCT ACA GGG AAA GGG CTA GAA TGA-3′
Click here for additional data file (aps201238x2.doc)
5′-aga tct ATG ACC CAG TCT CCT GCT TCC TTA GCT GTA TCT CTG GGG CAG AGG GCC ACC ATC TCA TAC AGG GCC AGC AAA AGT GTC AGT ACA TCT GGC TAT AGT TAT ATG CAC TGG AAC CAA CAG AAA CCA GGA CAG CCA CCC AGA CTC CTC ATC TAT CTT GTA TCC AAC CTA GAA TCT GGG GTC CCT GCC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC TTC ACC CTC AAC ATC CAT CCT GTG GAG GAG GAG GAT GCT GCA ACC TAT TAC TGT CAG CAC ATT AGG GAG CTT ACA CGT TCG GAG GAG GCA CCA AGC TGG GAA TTC GGT GGT GGT GGA TCC GGT GGT GGT GGT TCT GGC GGC GGC GGC TCC GTC GAC ATG AGT CCT GAA CTA ACC TTG AAT CTG AAG CAA AGG GGA TCA GCC CGA GAT TCT CAT TCA GTG ATC AAC ACT GAA CAC ACA TCC CTT ACC ATG GAT TTT GGG CTG ATT TTT TTT ATT GTT GCT CTT TTA AAA GGG GTC CAG TGT GAG GTG AAG CTT CTC GAG TCT GGA GGT GGC CTG GTG CAG CCT GGA GGA TCC CTG AAA CTC TCC TGT GCA GCC TCA GAA TTC GAT TTT AGT AGA TAC TGG ATG AGT TGG GTC CGG CAG GCT ACA GGG AAA GGG CTA GAA TGA GTT AAC-3′
Click here for additional data file (aps201238x3.doc)
Keywords: leukemia, CHMP5, monoclonal antibody, single chain variable fragment antibody (scFv), retrovirus, programmed cell death, apoptosis, necrosis, autophagy, apoptosis-inducing factor (AIF).
Previous Document: Efficacy of zoledronic acid in treatment of teoarthritis is dependent on the disease progression sta...
Next Document: Significantly Increased Pregnancy Rates After Laparoscopic Restorative Proctocolectomy: A Cross-Sect...